NCT03025542 - A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 27, 2016

Primary Completion Date

December 11, 2017

Study Completion Date

December 11, 2017

Conditions

Chronic Plaque Psoriasis

Interventions

DRUG

Bimekizumab

Based on their randomization subjects will receive a combination of several injections of Bimekizumab.

OTHER

Placebo

Subjects will receive injections of Placebo.

Trial Locations (8)

Ps0016 704, Bexley

Ps0016 102, Kogarah

Ps0016 101, Melbourne

Ps0016 104, Woolloongabba

Ps0016 201, Ajax

Ps0016 203, London

Ps0016 202, Windsor

Ps0016 501, Chisinau